PIMCO Global StocksPLUS and Income Fund
Change company Symbol lookup
Select an option...
PGP PIMCO Global StocksPLUS and Income Fund
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
OXBR Oxbridge Re Holdings Ltd
NVO Novo Nordisk A/S
JNJ Johnson & Johnson
SCHD Schwab U.S. Dividend Equity ETF™
PAYS Paysign Inc
ALTR Altair Engineering Inc
CVX Chevron Corp
ASCB ASPAC II Acquisition Corp
Go

Company profile

PIMCO Global StocksPLUS & Income Fund (the Fund) is a closed-end management investment company. The Fund's investment objective is to seek total return comprised of current income, current gains, and long-term capital appreciation. The Fund may engage in investment strategies, including those that employ the use of paired swaps transactions, the use of interest rate swaps to seek to capitalize on differences between short-term and long-term interest rates and other derivatives transactions. The Fund invests in securities, such as corporate bonds and notes, United States government agencies, loan participations and assignments, short-term instruments, non-agency mortgage-backed securities, asset-backed securities, preferred securities, sovereign issues, municipal bonds, and notes and other. It invests in various sectors, including banks, gaming, technology, health care, electric utility, and airlines, among others. Its investment manager is Pacific Investment Management Company LLC.

Closing Price
$6.44
Day's Change
0.06 (0.94%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.63
Day's Low
6.44
Volume
(Light)
Volume:
21,450

10-day average volume:
27,097
21,450

Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting

8:54 am ET May 29, 2022 (MarketWatch)
Print

Jaimy Lee

Arcellx shares surged, while Iovance Biotherapeutics and SpringWorks lost more than half their value

The stocks for companies developing cancer therapies were moving in morning trading on Friday as biotechs and researchers shared new clinical findings in advance of next week's American Society of Clinical Oncology annual meeting.

Here's a recap of Friday's big premarket moves:

The SPDR S&P Biotech ETF (XBI) was down 39.6% for the year, while the S&P 500 has declined 13.78%.

-Jaimy Lee

	

(END) Dow Jones Newswires

May 29, 2022 08:54 ET (12:54 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.